Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue? [Yahoo! Finance]
Ligand Pharmaceuticals (NASDAQ:LGND) had its price target raised by analysts at Royal Bank Of Canada from $234.00 to $235.00. They now have an "outperform" rating on the stock.
Ligand Pharmaceuticals (NASDAQ:LGND) had its price target raised by analysts at Stifel Nicolaus from $220.00 to $230.00. They now have a "buy" rating on the stock.
Ligand Pharmaceuticals (NASDAQ:LGND) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.